Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis (EXEL -1.97%) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Exelixis and see what CAPS investors are saying about the stock right now.
Exelixis facts
|
Headquarters (founded) |
South San Francisco, Calif. (1994) |
|
Market Cap |
$837.8 million |
|
Industry |
Biotechnology |
|
Trailing-12-Month Revenue |
$47.5 million |
|
Management |
Co-Founder/Chairman Dr. Stelios Papadopoulos |
|
Trailing-12-Month Return on Equity |
(76.3%) |
|
Cash/Debt |
$411.4 million / $335.7 million |
|
Competitors |
AstraZeneca |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 2,642 members who have rated Exelixis believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, JoeArizona, succinctly summed up the Exelixis bull case for our community:
Clinical trials are ongoing, and I don't anticipate much growth until the current round of trials show conclusive evidence that Cabozantinib is effective. But they already have one FDA approval under their belt, and as more come in the next few years, [Exelixis] will take off.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
